Fresenius USA Marketing, Inc.
$1.6M 10,547 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Zevra Therapeutics Inc
Zevra Therapeutics Inc reported $1,546,445.40 across General Payments, Research, and Ownership to 25 physicians and teaching hospitals across 103 transactions.
- $1.5M
- All-tracks total
- 103
- Transactions
- 25
- Recipients
- #516
- of 1,925 companies
Zevra Therapeutics Inc reported $1,546,445.40 across all CMS Open Payments tracks (General + Research + Ownership) to 25 physicians and teaching hospitals in Program Year 2024 - ranking #516 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $34,822.81, averaging $61.9K per recipient.
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer zevra-therapeutics-inc Zevra Therapeutics Inc
$1.5M · #516/1,925 · 0.0% industry · PY2024
- TOT $1.5M
- RANK #516
- SHARE 0.0%
- TXN 103
- RCP 25
- CAT 4
- GEN $34.8K
- TOP1 33.6%
- PY 2024
Volume peers
Nearest volume peer: Fresenius USA Marketing, Inc. ($1.6M)
Zevra Therapeutics Inc sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
What the Data Shows for Zevra Therapeutics Inc
$1,546,445.40: that is what Zevra Therapeutics Inc reported in payments to 25 physicians and teaching hospitals during Program Year 2024, spread across 103 transactions ($15.0K per transaction, $61.9K per recipient). The company sits at rank #516 of 1,925, a comparatively small 0.0% slice of all industry payments reported nationwide for the year.
Of the 4 general-payment categories charted below, "Consulting Fee" is the largest at $29.8K across 10 transactions, 85.7% of this company's General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
Across 4 types of general payments, Zevra Therapeutics Inc's largest category was "Consulting Fee" at $29.8K - 85.7% of General Payments.
Zevra Therapeutics Inc reports 4 general-payment categories - the top three are Consulting Fee (85.7%), Honoraria (7.9%), and Travel and Lodging (5.5%). The remaining 1 category make up 0.9% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
How Zevra Therapeutics Inc divides its payments
How the reported total splits across payment categories
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Consulting Fee | $29.8K | 10 | 85.7% |
| Honoraria | $2.8K | 1 | 7.9% |
| Travel and Lodging | $1.9K | 2 | 5.5% |
| Food and Beverage | $296.54 | 12 | 0.9% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $28,698.91 (82.4%) of $34,822.81 in this company's General Payments records across 22 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Zevra Therapeutics Inc
The five named recipients with the highest reported General Payments from this company
- 1
Chiadikaobi Uchendu Onyike
$11,700.00 across 1 reported transactions
- 2
Nathan Benjamin Fountain
$10,104.59 across 2 reported transactions
- 3
Karl S. Roth
$4,094.32 across 3 reported transactions
- 4
Holly Jean Bernal
$1,400.00 across 1 reported transactions
- 5
Stephanie J Offord
$1,400.00 across 1 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Zevra Therapeutics Inc's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Zevra Therapeutics Inc.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Zevra Therapeutics Inc.
Showing 6 of 1,924 companies with CMS-reported payment data.
Instylla, Inc.
$1.5M 124 recipients
Compare payment profiles
Balt USA, LLC
$1.5M 1,737 recipients
Compare payment profiles
Myriad Genetic Laboratories, Inc.
$1.6M 11,970 recipients
Compare payment profiles
Collegium Pharmaceutical, Inc.
$1.5M 36,863 recipients
Compare payment profiles
Invivyd Inc
$1.5M 268 recipients
Compare payment profiles
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.